Trade groups on bird flu
This article was originally published in The Tan Sheet
Executive Summary
"Marketers and retailers of dietary supplements are urged to refuse to stock or sell any products that are presented as preventing, treating or curing avian flu," a coalition of supplement industry trade groups announces in a joint advisory issued Nov. 18. The American Herbal Products Association, Consumer Healthcare Products Association, Council for Responsible Nutrition and National Nutritional Foods Association "encourag[e] consumers to use caution should they encounter products which claim to treat or prevent the avian flu" and note that "federal law and regulations do not allow any dietary supplement product" to make such claims. Although supplements can enhance general immune function, therapies for prevention or treatment of avian flu "should only be recommended by qualified healthcare professionals or public health authorities," the groups conclude...
You may also be interested in...
“Fowl” Play? FDA Warning Letters Target Avian Flu Supplement Marketers
Nine dietary supplement firms who received FDA warning letters for marketing their products as treatments for avian flu could face "far more serious enforcement activity" if they do not take "immediate corrective action," according to an industry lawyer
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.